Vanrafia
(Atrasentan)Phase 3Small molecule
NovartisAtrasentan is used to treat a kidney disease called IgA nephropathy by reducing protein leakage into the urine. The medication works by blocking a substance in the body that causes kidney inflammation, helping to slow the progression of the disease.[1] Vanrafia is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Vanrafia is one of 179 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.
7
Indications
15
Total Trials
2
Active Trials
178
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Vanrafia
NovartisPhase 3
Novantrone
PfizerPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Prednisone/prednisolone
RochePreclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Osmitrol
BB. Braun Medical Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer4 trials
Albuminuria2 trials
IgA Nephropathy2 trials
5 more indications
Coronary Artery Disease1 trial
Nephropathy1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Apr 2, 2025
VANRAFIA
NDA NDA219208
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atrasentan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]